|
| |
Information and News
1984-2005,
Cancer Research, Jurij A. Bogovic, MD ®
Conventional,
holistic, alternative, biologic support for cancer treatment,
consultations, counseling service, deliberation and individual complex program for You.
We propose
know-how for a new and very effective therapy option
Photodynamic therapy in the modern oncology
Advantages
of
the
photodynamic
therapy
-
high
affinity and accumulation in a tumour
-
treatment +
fluorescent diagnostics
-
üan
opportunity of repeated
treatment
-
ülow
cost
-
ütreatment
in out-patient
basis
-
ücosmetic
effect
Indications
for
PDT
-
üSkin
cancer,
cancer
of a mucous oral cavity, tongue,
lips
-
üEarly
stage central lung cancer,
obstructive lung cancer
-
üEarly
stage
esophageal
cancer, obstructive
esophageal
cancer
-
üEarly
gastric cancer
-
üSuperficial
bladder cancer
-
üCutaneous
metastases
of breast cancer
-
üCutaneous
metastases
of melanoma
-
üCervical
cancer,
cervical dysplasia
|
|
|
|
|
|
|
|
|
Skin Cancer 9 days after PDT |
|
|
|
|
|
|
|
|
|
|
|
|
Skin Cancer 4 weeks after PDT |
|
|
|
|
|
|
|
|
|
Prof. Istomin J. et al., 2003
Contact, Information
-
E-Mail
For Consultations:
contact@cancer-research.de
istomin@bcsmi.med.by
Information and some News for Download
Hyperthermia in Patients with
Prostate Cancer. News 2004
Prostate Cancer. News 2002-2004
Review on Molecular Targeting of Cancer:
Medical information see also by:
New
directions in the treatment of cancer - dose density chemotherapy,
we would
strongly recommend to support this approach!
-
Dose-Density
Improves Outcome of Chemotherapy in Breast Cancer, Laurie Barclay, MD
, Medscape Medical News 2002.
Based on a mathematical model called the Norton-Simon hypothesis, the
"dose dense" regimen administers doses of chemotherapy more
frequently, leading to a 31% improvement in survival compared with
conventional treatment with no increase in toxicity. "The idea of dose
density is really rather simple: give the drugs more often and don't
give more than you need. Then, each time you treat you'll be starting
with a smaller and smaller amount of cancer, because you're not giving
the cancer as much time to grow between treatments," says coauthor
Clifford Hudis, from MSKCC. "One of the exciting things about this
study is that it demonstrates we are able to shorten the time patients
have to be on chemotherapy, decrease the side effects, and at the same
time improve outcomes."
-
Fridik
MA, Havsmaniner H, Lang A, et al. Low risk patients with aggressive
non-Hodgkin's lymphoma have superior survival with dose density
chemotherapy. Proc Am
Soc Clin Oncol. 2003;22:573. Abstract 2306.
|
New directions in the treatment of
cancer - Sometimes, Less Is More
Antiangiogenesis Cocktails -- Stirred or Shaken?
Highlights of the 9th Annual Drug Discovery Technology World Congress;
August 8-13, 2004; Boston, Massachusetts
Sara M. Mariani, MD, PhD
Medscape General Medicine 6(4), 2004
Combinations of lower doses of CT drugs
-- metronomic CT -- with antiangiogenic compounds may, in principle, be
associated with lower CT-related toxicities and higher efficacy. Instead
of a pulsatile administration of the maximum tolerated dose every few
weeks, the patients would receive a lower, but continuous dosing of CT
agents. Endothelial cells damaged by the CT would not have time to
recover and repair the structural damages incurred, thus depriving
tumors of a support essential for growth and metastasis.[10-16]
Metronomic therapy has been used as adjuvant treatment in patients with
early-stage (T2) lung cancer, with low daily doses of uracil/tegafur,
for 2 years. Grade 3 toxicities were noted in only 2% of patients.[15]
It may thus be that less is more, as proposed by Doug Hanahan.[16]
Consistent with this hypothesis, chronic administration of low doses of
a vinblastin/DC101 combination (that has antiangiogenic activity)
achieved long-term control of the cancer in treated mice, after a
remission-induction regimen at higher doses. In addition, a combination
of trastuzumab with metronomic CT proved more active in delaying tumor
progression than either metronomic CT or trastuzumab alone in treated
mice.
In a study by Colleoni and colleagues[17,18] in breast cancer patients,
very low doses of methotrexate plus cyclophosphamide achieved an overall
response rate of 32%. Such treatment was not associated with alopecia,
nausea, and vomiting usually seen with these drugs given at the much
higher, intermittent doses. Of note, the cost of this metronomic
approach has been calculated at approximately $10/month. Further studies
are needed to confirm these findings in a larger number of patients. A
study is in progress in the United States and Canada that envisions the
association of bevacizumab with a methotrexate/cyclophosphamide
metronomic regimen.[6]
How can researchers identify and recommend optimal doses when they are
choosing metronomic CT regimens or associating antiangiogenesis
inhibitors? Easily accessible and readily measurable biomarkers would be
the optimal way. Along this line, techniques are being developed to
measure the number of circulating endothelial precursor cells (CEPCs) by
color flow cytometry, as a surrogate marker for the in vivo activity of
antiangiogenic agents and to evaluate the effects of metronomic CT on
tumor response and endothelium integrity.[19]
Objections have, however, been raised to this approach. The rate of
precursor cells in a newly forming endothelium, they say, is too
variable, ranging from 1% to 50% to make this surrogate marker reliable.
CEPCs may yield pericytes instead of endothelial cells. And others argue
that CEPCs are important in transplants but not in endogenous tumors.
Dr. Kerbel said that ultimately all this might not be important. What is
needed is just a biomarker that correlates well with the angiogenic and
vasculogenic phenotype in a number of experimental systems and mouse
strains. And in his view, the number of CEPCs is a biomarker that
effectively correlates with optimal doses of antiangiogenesis drugs. For
example, treatment of Nawal Burkitt's lymphoma in mice, with DC101 (800
mg), showed bioactivity of the drug and optimal effects on CEPC
levels.[6,19]
Similar results were obtained with vinblastine, docetaxel, and
cyclophosphamide, thus allowing the determination of the optimal
metronomic dose for each of these CT agents. For example, 20 mg/kg/day
was the dose of cyclophosphamide that best correlated with the optimal
inhibition of viable VEGFR-2+ CEPCs. Viability was determined through
measurement of VE-cadherin mRNA. Determination of viable CEPCs should
become, according to Dr. Kerbel, the standard assay to measure the
efficacy of antiangiogenesis agents.[6]
Medscape General Medicine 6(4), 2004 |
Scientific Project
Our goal is to modify the chemotherapy with hyperthermia
to achieve better
results in tumor therapy with less general toxicity.
"Experimental modification of Mitomycin C chemotherapy"
We would like to realize a scientific project with
experienced belarusian oncologists in the fundamental investigations of hyperthermia effects "Experimental modification of Mitomycin C chemotherapy", with a target - optimization of complex anticancer therapy. We will present the results in international
medical Journals, Congresses, Internet. Our program will be done in conformance with international norms of experimental trials. We beg You to support the fundamental investigations and scientists-oncologists in Belarus` to use their experience for world
oncology. The belarusian oncologists were among the pioneers in fundamental science of hyperthermia and it`s clinical using in the modern oncology.
Support
The belarusian
oncologists were among the pioneers in fundamental investigations of
hyperthermia effects and it`s clinical using in the modern conventional
oncology.
We
would beg You for support the scientists-oncologists in Belarus`.
Thank You for a voluntary benefaction and Support for Belarusian
Oncologists Foundation
Citibank AG
Kasernenstr. 10
40213 Duesseldorf, GERMANY
IBAN : DE 29300209002104611560
S.W.I.F.T-Code (BIC): CIPRDEDD
Key Words: 'Support for the fundamental investigations of hyperthermia
and Belarusian Oncologists'
|
Multidrug Resistance |
Hyperthermia
Effects |
Hyperthermia
Results |
| Bibliography
|
Contact
|
News and Information
|
|
|
Watchful
Waiting
in contrast to Radical Prostatectomy